If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Capromab Pendetide Imaging Leads to 91.7% Long-Term Disease-Free Survival for Prostate Cancer Patients: Presented at PCS By Ed Susman KISSIMMEE, FL -- February 27, 2007 -- Use of capromab pendetide (Prostascint)-based imaging improves the precision with which prostate cancer tumours can be viewed and can help determine the location and extent of the disease, researchers reported here at the 3rd Prostate cancer Symposium (PCS). Prostate cancer patients who were treated with brachytherapy after they underwent capromab pendetide (Prostascint)-based imaging achieved a 91.7% biochemical disease-free survival after 8 years, the researchers said. Use of combination single-photon emission computed tomography (SPECT) and computer-assisted tomography (CT) can help physicians determine if the prostate cancer is contained in the organ, and if that is the case, the chances of cure are enhanced. "The use of Prostascint brings a new level of precision to prostate cancer imaging by providing a clearer view of the location and extent of disease in and around the prostate," said Rodney Ellis, MD, assistant professor of urology, Case Western Reserve University, Cleveland, and radiation oncologist, Aultman Hospital, Canton, Ohio, United States. In a poster presentation on February 24th, Dr. Ellis said that the technology illustrates when the cancer is emerging from the prostate capsule, so clinicians can plan further therapy such as external beam radiation or hormonal treatments, if necessary. In his study of 236 patients imaged with SPECT/CT capromab pendetide, 203 cancers were located completely within the prostate and were treated accordingly. After 8 years, 91.7% of those patients had achieved a biochemical prostate cancer disease-free state, Dr. Ellis said. Biochemical disease following brachytherapy or external beam radiation is determined by a prostate specific antigen reading of 1 ng/mL. Increases in that reading is an indication of cancer's return and is considered a biochemical failure. Of the 11 patients in which the image showed cancer around the edges of the prostate, the 8-year survival was 72.7%, Dr. Ellis said. For the 22 patients with images clearly outside the prostate, survival dipped to 66.7%, he said, indicating that the imaging technology can differentiate between those patients who are clearly going to be helped by brachytherapy and those who will need additional treatment. "This study showed the value of functional imaging in prostate cancer,'' he said. He predicted that the studies will prompt doctors to take another look at the procedure. The symposium is cosponsored by the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology and the Society of Urologic Oncology. Dr. Ellis receives honoraria and research funding from Cytogen Inc., Princeton, New Jersey, United States.
[Presentation title: Eight-Year Biochemical Disease Free Survival Following Permanent Prostate Brachytherapy With Dose Escalation to Biologic Target Volumes Identified With SPECT/CT Capromab Pendetide. Abstract 357]
|
